UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain

You need to be a subscriber to read this article.
Click here to find out more.

The UK Budget, delivered last week, offers pharmaceutical manufacturers a mixed package: targeted wins on VAT, investment and capital allowances, but little relief on labour costs and key decisions deferred to the 2027 Spending Review.

Here is Manufacturing Chemist's take on what the new Budget means for manufacturers in the UK and for those supplying or investing in the market from overseas.

Which Budget measures matter most to pharma manufacturers?

The headline pharma measure is the confirmation of a VAT zero rate on qualifying medicines supplied free of charge.

UK Budget 2026: what it means for pharma manufacturingFirst announced in June this year (and taking effect retrospectively from 23 June), the confirmation of the measure settles a long-running issue: companies could previously face an output VAT bill on medicines they donated for early access, compassionate use, clinical trials and post-trial treatment, potentially putting these programmes under pressure.

“Removing the VAT charge on medicines that companies provide free of charge is a significant win for patients, lifting a barrier to access, protecting continuity of care and supporting the clinical research that brings new treatments to the UK," said Joe Edwards, Executive Director, UK Competitiveness, ABPI.

Capital allowances are more nuanced, however.

The government has maintained its commitment to capping corporation tax at 25% and retaining full expensing for eligible assets.

But, it will increase the main rate first-year allowance from 40% to 50% for expenditure incurred from 1 January 2027, while reducing the main writing-down allowance rate by two percentage points, from 14% to 12%, in April 2027.

In effect, the changes increase upfront tax relief for certain new investments while reducing the ongoing relief available for assets subject to the writing-down allowance.

Is the UK still attractive for pharma manufacturing investment?

It seems so. The Budget's showpiece was three public-private life sciences investment deals worth more than £1bn, backed by almost £70m in government grants.

The announcements span medical technology R&D, pharmaceutical research and drug delivery manufacturing:

  • Convatec will invest more than £500m during the next decade in a new global R&D hub in Manchester
  • Vertex Pharmaceuticals will invest more than £300m in a new facility in Oxford
  • and Kindeva will invest £200m in Loughborough to expand its drug delivery and respiratory medicines manufacturing capabilities.

New powers under the Regulation for Growth Bill will also allow innovative products, including medicines, to be tested under temporary, controlled regulatory changes.

The Faculty of Pharmaceutical Medicine welcomed the move, saying it comes as international competition for life sciences investment intensifies.

“This is a Budget that has much to welcome for the life sciences with fresh and faster injections of capital, lower energy costs, protection of the patent box and a focus on founders," said Chris Molloy, CEO, BioIndustry Association (BIA).

How will rising costs affect pharma manufacturers?

Energy and labour remain pain points. The Budget document says wholesale UK gas prices have risen almost 200% since the Middle East conflict began.UK Budget 2026: what it means for pharma manufacturing

However, the government said that it will give 10,000 energy-intensive manufacturers a 20-25% electricity discount from April 2027 under its British Industrial Competitiveness Scheme — but, eligibility criteria will determine how many pharma sites benefit.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like